Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

21.1%

4 terminated out of 19 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

58%

7 of 12 completed with results

Key Signals

7 with results75% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (3)
Early P 1 (1)
P 1 (4)
P 2 (11)

Trial Status

Completed12
Terminated4
Withdrawn2
Active Not Recruiting1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT01064648Phase 1Active Not Recruiting

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

NCT03420963Phase 1Terminated

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

NCT04213794Early Phase 1Terminated

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT01503177Phase 1CompletedPrimary

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

NCT01126346Not ApplicableCompleted

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT01325753Not ApplicableWithdrawn

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

NCT00365053Phase 2Completed

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

NCT00243074Phase 2Completed

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

NCT01861301Phase 2Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

NCT00459862Phase 2Completed

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

NCT00309946Phase 2Completed

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

NCT00392444Phase 2Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

NCT00027703Phase 2Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT01105390Phase 2Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

NCT00107432Phase 2Completed

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

NCT00039182Phase 2Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

NCT00025207Phase 2Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

NCT00028782Not ApplicableTerminated

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

NCT00030498Phase 1Completed

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Showing all 19 trials

Research Network

Activity Timeline